![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Schedules Meeting on Type 2 Diabetes Treatments
FDA Schedules Meeting on Type 2 Diabetes Treatments
September 19, 2018
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will meet at the agency’s White Oak campus on Oct. 24-25 to discuss guidance on antidiabetic therapies for treating Type 2 diabetes.
The committee will consider the agency’s guidance on Diabetes Mellitus—Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes.
The expert group will also discuss the cardiovascular risk assessment of Type 2 diabetes mellitus treatments.
Upcoming Events
-
21Oct